Sector
PharmaceuticalsOpen
₹32Prev. Close
₹29.7Turnover(Lac.)
₹19.24Day's High
₹35.64Day's Low
₹3252 Week's High
₹36.4752 Week's Low
₹22.8Book Value
₹20.42Face Value
₹10Mkt Cap (₹ Cr.)
7.48P/E
56.57EPS
0.63Divi. Yield
021 Aug 2024
12:00 AM
AGM
Announcement Date: 21 Aug, 2024
26 May 2025
12:00 AM
Board Meeting
Agenda : Audited Result
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 2.1 | 2.1 | 2.1 | 1.2 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 2.06 | 2.01 | 2 | 0.1 |
Net Worth | 4.16 | 4.11 | 4.1 | 1.3 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2019 |
|---|---|---|---|
Revenue | 3.05 | 7.51 | 2.76 |
yoy growth (%) | -59.32 | 172.18 | |
Raw materials | -2.73 | -6.88 | -1.82 |
As % of sales | 89.36 | 91.65 | 66.03 |
Employee costs | -0.14 | -0.2 | -0.3 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2019 |
|---|---|---|---|
Profit before tax | 0.04 | 0.09 | 0 |
Depreciation | -0.01 | -0.01 | -0.02 |
Tax paid | -0.01 | -0.03 | 0 |
Working capital | 0.23 | -1.4 | |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2019 |
|---|---|---|---|
Growth matrix (%) | |||
Revenue growth | -59.32 | 172.18 | |
Op profit growth | -80.11 | -0.31 | |
EBIT growth | -83.67 | 2.37 | |
Net profit growth | -56.16 | 68,800 |
| Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 |
|---|---|---|---|
Gross Sales | 18.04 | 21.08 | 3.36 |
Excise Duty | 0 | 0 | 0 |
Net Sales | 18.04 | 21.08 | 3.36 |
Other Operating Income | 0 | 0 | 0 |
Other Income | 0.29 | 0.01 | 0.02 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,647.65 | 92.31 | 3,95,326.43 | 2,000.46 | 0.97 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,537.95 | 78.57 | 1,73,562.03 | 667 | 0.46 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,498.35 | 24.58 | 1,21,022.9 | 1,485.4 | 1.07 | 4,254.47 | 397.41 |
Dr Reddys Laboratories Ltd DRREDDY | 1,312.75 | 20.48 | 1,09,550.72 | 1,200.7 | 0.61 | 5,546.3 | 345.79 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,226.65 | 57.31 | 1,09,199.59 | 474 | 0.99 | 2,385 | 224.33 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Managing Director
Aditya Mahavir Jain
Non Executive Director
Arihant Jain
Independent Non Exe. Director
Tesu Alakh
Non-Exec & Non-Independent Dir
Sumit Malik
Executive Director
Nitin Mehra
105 1st Floor Barodia Tower,
Central Market Prashant Vihar,
New Delhi - 110085
Tel: +91-988390021/9215324221
Website: http://www.fabinolife.com
Email: info@fabinolife.com
Tel: -
Website: -
Email: -
Summary
Fabino Enterprises Limited is a growing pharmaceutical company promoted by Atul Kumar Jain. The Company was incorporated as Fabino Life Sciences Private Limited on October 27, 2011 with the Registrar ...
Read More
Reports by Fabino Life Sciences Ltd
What is the Fabino Enterprises Ltd share price today?
What is the Market Cap of Fabino Enterprises Ltd?
What is the PE and PB ratio of Fabino Enterprises Ltd?
What is the 52 Week High and Low of Fabino Enterprises Ltd?
What is the CAGR of Fabino Enterprises Ltd?
What is the shareholding pattern of Fabino Enterprises Ltd?
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.